Dr. Sameer Mehta has proposed and advocated for a new medical specialty of the STEMI Interventionist with his work in performing angioplasty for treating heart attacks. Mehta is the author of three textbooks on STEMI interventions, and he has pioneered the development of population-based heart attack programs in several countries including China, India, Brazil, Russia, Malaysia, Thailand, Puerto Rico, Mexico and Colombia.

Dr. Mehta was Chief of Interventional Cardiology and Director of Cardiac Catheterization Laboratory at Cedars Medical Center in Miami (1995-2002), and he was President of the Miami-Dade chapter of the American Heart Association (1999, 2000). He also served as Chairman of the Institutional Review Board at the Miami Heart Institute (1993, 1994) as well as at Cedars Medical Center (1998 – 2001). Mehta has taken educational roles in angioplasty, including laser angioplasty, atherectomy, and stenting in numerous countries, and he is an author on more than 100 scientific publications. He is the founder of the Indian Society of Interventional Cardiologists and a Voluntary Associate Professor of Medicine at the University of Miami – Miller School of Medicine.

Mehta is the Chief Scientific Officer, Asia, for the Medicines Company. His primary role in this position is to assist the Medicines Company in conducting randomized, multi-center clinical trials and several physician-directed registry studies. His other work includes guiding the company with the launch of its newly developed intensive care products for PCI in the Asian PCI markets.

Dr. Roberto Botelho is the director of the Triangulo Heart Institute and also of its Interventional Cardiology and Clinical Research Divisions. Dr. Botelho completed his residency, and fellowship at Dante Pazzanese Heart Institute, in Sao Paulo and his Ph.D at the University of Sao Paulo School of Medicine. He also completed an interventional cardiology fellowship at Dante Pazzanese Heart Institute. The Scholars In Clinical Trials Course from Harvard University School of Medicine certified Dr. Botelho on 2008. Dr. Botelho is the president of the International Telemedical Systems ITMS. Dr. Botelho sits on the review boards of the International Journal of Cardiology and also for the Journal of the Brazilian Society of Interventional Cardiology. He is a member of the Ethical Review Board of the Uberlandia Federal University. He is co-author of more than 50 published peer-reviewed journal articles and abstracts and 10 book chapters. Dr. Botelho also directs the Triangulo Heart Institute Research Division and is principal investigator for over 30 ongoing multicenter clinical and device studies within the research laboratory. Over the past 5 years, these trials have included a broad array of new technology, including bare metal stents, drug-eluting stents, bioresorbable polimers, bioresorbable vascular scaffold, Nitinol, electrical released, self expandable stent platforms, several new molecules, like Ticagrelor, Cangrelor, Apixaban, Otamixaban, Aleglitazar, Saxagliptin, Alogliptin, Dronedarone, Dalcetrapid, and Technical new approaches as radial approach for interventional cardiology. Dr. Botelho s primary clinical interest is currently acute coronary syndromes.

Director of Interventional Cardiology Clinique Pasteur, Toulouse, France Director, Euro PCR President, European Association for Percutaneous Cardiovascular Interventions (EAPCI).